Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Acceleron looks past VEGF in cancer treatment

Friday, November 6th, 2009

Many cancer treatments being developed in the clinic focus on the VEGF pathway by blocking multiple kinase inhibitors or different proliferative agents simultaneously, which usually leads to serious side effects. But VEGF is just one piece of the tumor angiogenesis puzzle. Executives with Acceleron Pharma Inc. believe that a need exists ...

Posted in cancer, clinical trials | 1 Comment »

   
about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2010 Canon Communications Pharmaceutical Media Group